UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-A

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) or (g) OF THE
SECURITIES EXCHANGE ACT OF 1934

Pure Bioscience

(Exact name of registrant as specified in its charter)

State of California	33-0530289
(State of incorporation or organization)	(I.R.S. Employer Identification No.)

1725 Gillespie Way
El Cajon, CA 92020

(Address of principal executive offices)   (Zip Code)

Securities to be registered pursuant to Section 12(b) of the Act:

Title of Each Class to be Registered	Exchange
Common Stock	NASDAQ CAPITAL MARKET

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), check the following box.    [X]

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), check the following box.   [_]

Securities Act registration statement file number to which this form relates:    NA (if applicable)

Securities to be registered pursuant to Section 12(g) of the Exchange Act:      None.

INFORMATION REQUIRED IN REGISTRATION STATEMENT

Item 1.   Description of Registrant’s Securities to be Registered:

Pure Bioscience is authorized to issue up to 50,000,000 shares of our no par value common stock. Each share is entitled to one vote on matters submitted to a vote of the shareholders. There is no cumulative voting of the common stock. The common stock shares have no redemption provisions nor any preemptive rights. We are also authorized to issue up to 5,000,000 shares of preferred stock, the rights and preferences of which may be set from time to time prior to issuance by the Board of Directors.

Item 2.   Exhibits

3.1 (1) -- Articles of Incorporation, Articles of Amendment and Bylaws

3.1.1 (2) -- Articles of Amendment dated March 11, 2002

4.3 (1) -- Form of common stock Certificate

(1) Incorporated by reference from Form SB-2 registration statement SEC File #333-00434 effective August 8, 1996

(2) Incorporated by reference from the Annual Report on Form 10KSB for the fiscal year ended July 31, 2002 filed on October 29, 2003

SIGNATURE

         Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this amendment to its registration statement on Form 8-A to be signed on its behalf by the undersigned, thereto duly authorized.

                      
                      
                      
Date: March 31, 2008 PURE BIOSCIENCE
                            
                            
By: /s/ Michael L. Krall
Michael L. Krall, President